Turning Point Therapeutics (TPTX) Downgraded by JMP Securities to Market Perform

Turning Point Therapeutics stock has undergone multiple analysts rating changes in the recent past.  Turning Point Therapeutics Downgraded by JMP Securities on 10-11-21. In a note to investors, the firm issued a new rating of Market Perform. The analysts previously had rating of Outperform.

Shares of Turning Point Therapeutics traded down -$1.89 on Monday, reaching $45.87. 887266 shares of the stock traded hands, compared to its average volume of 448413. Shares of Turning Point Therapeutics were trading at $45.87 on Monday. The firm’s 50 day moving average is $70.01 and its 200 day moving average is $87.45.Turning Point Therapeutics has a 12 month low of $45.08 and a 12 month high of $141.30. While on yearly highs and lows, Turning Point Therapeutics’s today has traded high as $46.74 and has touched $45.08 on the downward trend. See More Analyst Rating at: RATING

Turning Point Therapeutics Earnings and What to expect: 

Turning Point Therapeutics last issued its earnings data on August 9th, 2021. The reported ($1.14) earnings per share for the quarter, beating the consensus estimate of ($1.20) by $0.06. The business had revenue of $5.16 million for the quarter. Turning Point Therapeutics has generated ($3.85) earnings per share over the last year (($3.31) diluted earnings per share). Earnings for Turning Point Therapeutics are expected to decrease in the coming year, from ($4.51) to ($6.55) per share. Turning Point Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 11th, 2021 based off prior year’s report dates.

Earnings for Turning Point Therapeutics are expected to decrease in the coming year, from ($4.51) to ($6.55) per share. The P/E ratio of Turning Point Therapeutics is -13.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Turning Point Therapeutics is -13.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Turning Point Therapeutics has a P/B Ratio of 1.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Turning Point Therapeutics (TPTX) Moving Average Technical Analysis

5 day Moving Average is $52.61 And 5 day price change is -$21.09 (-31.50%)  with average volume for 5 day average is 1,348,120. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $68.65 and 20 day price change is -$33.39 (-42.13%) and average 20 day moving volume is 570,190. 50 day moving average is $70.01  and 50 day price change is -$17.95 ( -28.13%)  and with average volume for 50 days is : 394,780. 200 day moving average is $87.45  and 200 day price change is -$84.69 (-64.87%)  and with average volume for 200 days is : 410,150.

Other owners latest trading in Turning Point Therapeutics :

  • On 9/3/2021 shares held by Parametric Portfolio Associates LLC were 20,755 which equates to market value of $1.62M and appx 0.00% owners of Turning Point Therapeutics
  • On 8/23/2021 shares held by Morgan Stanley were 53,882 which equates to market value of $4.20M and appx 0.00% owners of Turning Point Therapeutics
  • On 8/17/2021 shares held by Wells Fargo & Company MN were 647,184 which equates to market value of $50.49M and appx 0.00% owners of Turning Point Therapeutics
  • In total Institutional ownership equates to Institutional Ownership Percentage: 92.32% for Turning Point Therapeutics

See More Analyst Rating at: RATING